CA3172351A1 - Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof - Google Patents

Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof

Info

Publication number
CA3172351A1
CA3172351A1 CA3172351A CA3172351A CA3172351A1 CA 3172351 A1 CA3172351 A1 CA 3172351A1 CA 3172351 A CA3172351 A CA 3172351A CA 3172351 A CA3172351 A CA 3172351A CA 3172351 A1 CA3172351 A1 CA 3172351A1
Authority
CA
Canada
Prior art keywords
optionally substituted
independently
alkyl
acid
polyunsaturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3172351A
Other languages
English (en)
French (fr)
Inventor
Dragoslav VIDOVIC
Mikhail Sergeevich Shchepinov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Retrotope Inc
Original Assignee
Retrotope Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retrotope Inc filed Critical Retrotope Inc
Publication of CA3172351A1 publication Critical patent/CA3172351A1/en
Pending legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/1616—Coordination complexes, e.g. organometallic complexes, immobilised on an inorganic support, e.g. ship-in-a-bottle type catalysts
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/18—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
    • B01J31/1805—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
    • B01J31/2208—Oxygen, e.g. acetylacetonates
    • B01J31/2226—Anionic ligands, i.e. the overall ligand carries at least one formal negative charge
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2282—Unsaturated compounds used as ligands
    • B01J31/2295—Cyclic compounds, e.g. cyclopentadienyls
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F17/00—Metallocenes
    • C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/12—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by hydrogenation
    • C11C3/126—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by hydrogenation using catalysts based principally on other metals or derivates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/02—Compositional aspects of complexes used, e.g. polynuclearity
    • B01J2531/0202—Polynuclearity
    • B01J2531/0205—Bi- or polynuclear complexes, i.e. comprising two or more metal coordination centres, without metal-metal bonds, e.g. Cp(Lx)Zr-imidazole-Zr(Lx)Cp
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/821—Ruthenium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/822—Rhodium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/827—Iridium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2540/00—Compositional aspects of coordination complexes or ligands in catalyst systems
    • B01J2540/60—Groups characterized by their function
    • B01J2540/62—Activating groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Fats And Perfumes (AREA)
CA3172351A 2020-02-21 2021-02-19 Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof Pending CA3172351A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062979627P 2020-02-21 2020-02-21
US62/979,627 2020-02-21
PCT/US2021/018861 WO2021168311A1 (en) 2020-02-21 2021-02-19 Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof

Publications (1)

Publication Number Publication Date
CA3172351A1 true CA3172351A1 (en) 2021-08-26

Family

ID=77391771

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3172351A Pending CA3172351A1 (en) 2020-02-21 2021-02-19 Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof

Country Status (9)

Country Link
US (2) US11779910B2 (enExample)
EP (1) EP4107163A4 (enExample)
JP (2) JP7850898B2 (enExample)
KR (2) KR20260018193A (enExample)
CN (1) CN116438187A (enExample)
AU (1) AU2021224854A1 (enExample)
CA (1) CA3172351A1 (enExample)
IL (2) IL321252A (enExample)
WO (1) WO2021168311A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017091279A1 (en) 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
EP4107163A4 (en) 2020-02-21 2024-06-19 Retrotope, Inc. PROCESSES FOR ISOTOPIC MODIFICATION OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES
CA3243042A1 (en) * 2021-12-21 2025-04-08 Biojiva Llc METHODS AND COMPOSITIONS INTENDED FOR THE TREATMENT OF INFLAMMATORY DISEASE

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520872A (en) 1967-03-24 1970-07-21 Upjohn Co Process for labelling purine and pyrimidine containing compounds
US4792620A (en) 1983-10-14 1988-12-20 Bp Chemicals Limited Carbonylation catalysts
IT1205043B (it) 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
US5340742A (en) 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
AU620929B2 (en) 1988-10-27 1992-02-27 Bar-Ilan University Method and compositions for treating alzheimer's disease, related dementias and epilepsy
DK0455783T3 (da) 1989-11-30 1996-04-01 Croda Int Plc Anvendelse af nervonsyre og langkædede fedtsyrer til behandlingen af demyeliniserende sygdomme
ES2033193B1 (es) 1990-10-30 1994-01-16 Ganadera Union Ind Agro Mezcla grasa para nutricion infantil y de adultos.
EP0567653A4 (en) 1991-11-14 1994-06-01 Sagami Chem Res Drug for hepatic diseases
JPH05246938A (ja) 1992-02-19 1993-09-24 Sagami Chem Res Center 重水素標識高級脂肪酸
CN1152316A (zh) 1994-05-19 1997-06-18 麦克公司 具有烯丙基的甾族化合物的氧化
FR2721518B3 (fr) 1994-06-28 1996-04-12 Gattefosse Ets Sa Compositions cosmétiques, pharmaceutiques, diététiques, vétérinaires contenant de l'eau.
FR2722410B1 (fr) 1994-07-15 1996-10-04 Grinda Jean Robert Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises entherapeutique
GB9423625D0 (en) 1994-11-23 1995-01-11 Scotia Holdings Plc Fortified fruit juice
JPH08268885A (ja) 1995-03-30 1996-10-15 Oyo Seikagaku Kenkyusho 過酸化脂質増量抑制剤
US5578334A (en) 1995-04-07 1996-11-26 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serum with fat blends
CN1114878A (zh) 1995-06-09 1996-01-17 郑州铁路局中心医院 一种防治心血管系统疾病的制剂
JPH0950274A (ja) 1995-08-07 1997-02-18 Kawai Musical Instr Mfg Co Ltd アップライトピアノのフレーム
JPH09143492A (ja) 1995-11-17 1997-06-03 Katsumasa Koike 酸化脂質の確認方法及び酸化脂質の生成方法
JPH10291955A (ja) 1997-04-22 1998-11-04 Sagami Chem Res Center １３ｃ標識ドコサヘキサエン酸及びその製造方法
JPH1070439A (ja) 1996-08-29 1998-03-10 Hitachi Ltd 受信装置
US20030013772A1 (en) 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US6111066A (en) 1997-09-02 2000-08-29 Martek Biosciences Corporation Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains
DE69832984T2 (de) 1997-10-08 2006-09-21 Isotechnika, Inc., Edmonton DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN
US6270974B1 (en) 1998-03-13 2001-08-07 Promega Corporation Exogenous nucleic acid detection
US6468802B1 (en) 1998-05-06 2002-10-22 Isotechnika, Inc. 13C glucose breath test for the diagnosis of diabetic indications and monitoring glycemic control
CN1326344A (zh) 1998-10-15 2001-12-12 Dsm公司 Pufa增补剂
IT1304406B1 (it) 1998-10-21 2001-03-19 Danital Italia S R L Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
US6503478B2 (en) 1999-01-13 2003-01-07 Lightouch Medical, Inc. Chemically specific imaging of tissue
US7271315B2 (en) 1999-01-14 2007-09-18 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
JP2000290291A (ja) 1999-03-31 2000-10-17 Nippon Sanso Corp 安定同位体標識オリゴヌクレオチド及びオリゴヌクレオチド検出方法
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
ITMI991894A1 (it) 1999-09-09 2001-03-09 Carlo Ghisalberti Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso
JP3432778B2 (ja) 1999-11-19 2003-08-04 森澤 紳勝 活性酸素消去剤の濃縮液、その製造方法および活性酸素消去剤パウダー
GB9929897D0 (en) 1999-12-18 2000-02-09 Slabas Antoni R Improvements in or relating to conjugated fatty acids and related compounds
JP2001270832A (ja) 2000-03-27 2001-10-02 Ito En Ltd 網膜障害予防剤
GB2368339B (en) 2000-10-26 2002-09-18 Yissum Res Dev Co Complex incorporating a plurality of antioxidants
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US20020198177A1 (en) 2001-05-30 2002-12-26 Horrobin David Frederick Coenzyme Q and EPA
GB0113348D0 (en) 2001-06-01 2001-07-25 Mars Uk Ltd Skin diet
WO2003035095A1 (en) 2001-10-19 2003-05-01 Maxim Pharmaceuticals, Inc. Use of histamine to treat liver disease
US6870077B2 (en) 2002-01-30 2005-03-22 Edward O. Kenaschuk High linolenic acid flax
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
JP2004081156A (ja) 2002-08-28 2004-03-18 Shigeo Ota 糖尿病および糖尿病関連疾患の予測のためのマーカーおよび個体分類方法
EP1548116A4 (en) 2002-09-30 2006-04-05 Ajinomoto Kk PROCESS FOR PRODUCING A PROTEIN MARKED BY A STABLE ISOTOPE
US7795203B2 (en) 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
MXPA05005240A (es) 2002-12-06 2005-07-25 Alcon Inc Imitadores de la superoxido - dismutasa para el tratamiento de desordenes y enfermedades oculares.
TW200413274A (en) 2002-12-27 2004-08-01 Wako Pure Chem Ind Ltd Deuteration or tritiation method
KR20050029582A (ko) 2003-09-23 2005-03-28 주식회사 리포젠 알지닌 공액리놀레인산 복합체를 포함하는 항산화 조성물
IL158552A0 (en) 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
EP1713463A4 (en) 2004-01-19 2009-03-18 Martek Biosciences Corp REELIN LACK OR DYSFUNCTION AND RELEVANT PROCEDURE
US20050164908A1 (en) 2004-01-23 2005-07-28 Ginsberg Myron D. Neuroprotective complex for treatment of cerebral ischemia and injury
JP2008504372A (ja) 2004-06-18 2008-02-14 ニューロケム （インターナショナル） リミティッド β−アミロイド関連疾患の治療のための治療用製剤
US20090232916A1 (en) 2004-08-09 2009-09-17 Avidor Shulman Food products for diabetics
JP2006053100A (ja) 2004-08-13 2006-02-23 Institute Of Physical & Chemical Research 動物の代謝解析方法、ラベル動物の製造方法、ラベル動物、および、動物のｎｍｒ測定方法
CA2588166A1 (en) 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
WO2006073147A1 (ja) 2005-01-04 2006-07-13 Mochida Pharmaceutical Co., Ltd. 脂肪毒性の改善剤
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US20070004639A1 (en) 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
KR20130101596A (ko) 2005-07-08 2013-09-13 마텍 바이오싸이언스스 코포레이션 치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산
JP2009525948A (ja) 2005-12-20 2009-07-16 シラメッド・インコーポレーテッド 高親油性スルフヒドリル化合物の製薬組成物及び使用方法
EP1973536A2 (en) 2006-01-05 2008-10-01 Reliant Pharmaceuticals, Inc. Treatment of fatty liver
WO2007081910A2 (en) 2006-01-05 2007-07-19 Kinemed, Inc. Compositions and methods of treatment using modulators of motonueron diseases
JP5137168B2 (ja) 2006-02-27 2013-02-06 独立行政法人科学技術振興機構 安定同位体標識脂肪族アミノ酸、その標的蛋白質への組み込み方法並びに蛋白質のｎｍｒ構造解析方法
GB0604647D0 (en) 2006-03-08 2006-04-19 Shchepinov Mikhail Stabilized food supplements and their derivatives
WO2008143642A2 (en) 2006-11-09 2008-11-27 Children's Medical Center Corporation Methods of treating and preventing ocular neovascularization with omega-3 polyunsaturated fatty acids
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP1961311A1 (en) 2007-02-23 2008-08-27 Belovo S.A., Egg Science & Technology Food comprising polyunsaturated fatty acids for the prevention of chronic diseases
CN101677564A (zh) 2007-03-14 2010-03-24 诺普神经科学股份有限公司 (6r)-4,5,6,7-四氢-n6-丙基-2,6-苯并噻唑-二胺的改良释放制剂及其使用方法
US20080234197A1 (en) 2007-03-19 2008-09-25 Undurti N Das Method(s) of stabilizing and potentiating the actions and administration of brain-derived neurotrophic factor (BDNF)
WO2008146721A1 (ja) 2007-05-25 2008-12-04 Santen Pharmaceutical Co., Ltd. 加齢黄斑変性の予防又は治療剤
US8501032B2 (en) * 2007-07-26 2013-08-06 San Diego State University (Sdsu) Foundation Catalysts for alkene isomerization and conjugating double bonds in polyunsaturated fats and oils
CA2693310C (en) 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
US20090069354A1 (en) 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched gemcitabine
KR20100100818A (ko) 2007-10-31 2010-09-15 프로노바 바이오파마 노르지 에이에스 새로운 ｄｈａ 유도체 및 약물로서 그들의 사용
US8021874B2 (en) 2008-01-28 2011-09-20 The Board Of Regents Of The University Of Oklahoma Very long chain polyunsaturated fatty acids, methods of production, and uses
DK2268604T3 (en) 2008-03-14 2017-03-27 Retrotope Inc CANCER THERAPIES BY USING ISOTO-SUBSTITUTED LYSIN
US8637486B2 (en) 2008-03-14 2014-01-28 Retrotope, Inc. Therapeutic substances that modulate genome methylation
EP2110027A1 (en) 2008-04-01 2009-10-21 Nestec S.A. Long-chain polyunsaturated fatty acids (LC-PUFA) in maternal nutrition during pregnancy and lactation
CN102056907B (zh) 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
DK2280928T3 (en) 2008-05-01 2018-11-05 Complexa Inc Vinyl-substituted fatty acids
JPWO2009151125A1 (ja) 2008-06-13 2011-11-17 持田製薬株式会社 肝障害の診断及び治療
GB0813599D0 (en) 2008-07-24 2008-09-03 Pharma Marine As Method
EP3403650A3 (en) 2008-07-28 2019-02-13 Blanchette Rockefeller Neurosciences, Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
JP5030175B2 (ja) 2008-09-11 2012-09-19 独立行政法人産業技術総合研究所 重水素化化合物製造用触媒及びそれを用いた重水素化化合物の製造方法
EP2375900B1 (en) 2008-12-11 2016-03-02 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
US20120046363A1 (en) 2009-05-11 2012-02-23 University Of Maryland, Baltimore Docosahexaenoic acid for the treatment of heart failure
WO2010143053A1 (en) 2009-06-10 2010-12-16 Energy4Life Ag Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
DK2493296T3 (en) 2009-10-30 2019-04-15 Retrotope Inc REMOVAL OF OXIDATIVE STRESS STATES WITH PUFA DERIVATIVES
WO2011097273A1 (en) 2010-02-02 2011-08-11 Martek Biosciences Corporation Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine
JP5896472B2 (ja) 2010-11-16 2016-03-30 株式会社 西崎創薬研究所 ＰＫＣ−ε活性化剤
US10154983B2 (en) 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
WO2012148929A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Disorders implicating pufa oxidation
KR102020579B1 (ko) 2011-04-26 2019-09-10 레트로토프 인코포레이티드 에너지 프로세싱 손상 장애 및 미토콘드리아 결함
US10058522B2 (en) 2011-04-26 2018-08-28 Retrotope, Inc. Oxidative retinal diseases
WO2012174262A2 (en) 2011-06-14 2012-12-20 Cenestra Llc Formulations and methods of treating subjects having central nervous system, endocrine, inflammatory or cardiovascular disorders or at-risk thereof with highly purified omega-3 fatty acid formulations
AU2015229240B9 (en) * 2014-03-13 2019-05-02 Biojiva Llc Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances
WO2015162265A1 (en) 2014-04-24 2015-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) New lipophenol compounds and uses thereof
WO2017091279A1 (en) * 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
CN107569684B (zh) 2016-07-05 2021-04-09 杰尼视界公司 生发配方
CA3056882A1 (en) * 2017-03-20 2018-09-27 University Of Southern California Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
EP4107163A4 (en) 2020-02-21 2024-06-19 Retrotope, Inc. PROCESSES FOR ISOTOPIC MODIFICATION OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES

Also Published As

Publication number Publication date
IL295783B1 (en) 2025-11-01
KR20260018193A (ko) 2026-02-06
IL321252A (en) 2025-08-01
CN116438187A (zh) 2023-07-14
JP2023514711A (ja) 2023-04-07
KR20220143931A (ko) 2022-10-25
IL295783A (en) 2022-10-01
US20240091752A1 (en) 2024-03-21
EP4107163A4 (en) 2024-06-19
JP7850898B2 (ja) 2026-04-24
US11779910B2 (en) 2023-10-10
IL295783B2 (en) 2026-03-01
AU2021224854A1 (en) 2022-10-06
EP4107163A1 (en) 2022-12-28
WO2021168311A1 (en) 2021-08-26
US20210269376A1 (en) 2021-09-02
JP2026032064A (ja) 2026-02-25

Similar Documents

Publication Publication Date Title
US20240091752A1 (en) Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
AU2021225202B2 (en) Site-specific isotopic labeling of 1, 4-diene systems
AU2011288410B2 (en) Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases
HK40057018A (en) Site-specific isotopic labeling of 1, 4-diene systems
HK40068751A (en) Site-specific isotopic labeling of 1,4-diene systems
HK1261107B (en) Site-specific isotopic labeling of 1, 4-diene systems
OA16321A (en) Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases.

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250214

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250214

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250214

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250224

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250304

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250304

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250304

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250501

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250508

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260213

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260213

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260220

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260622

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260709

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260709

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260709